Retatrutide mechanism of action.

Retatrutide (development code LY3437943) is a 39-residue synthetic peptide engineered to activate three distinct class-B G-protein-coupled receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon receptor (GCGR). Unlike modified analogues of a single hormone, its sequence combines structural features from all three parent peptides to allow balanced binding at each site (Coskun et al., 2022).

All three targets are members of the secretin family of GPCRs, sharing a large N-terminal extracellular domain that binds the C-terminal helix of the peptide agonist, and a seven-transmembrane bundle that engages the N-terminal residues to initiate signalling. In each case the dominant downstream coupling is via the stimulatory Gαs protein, activation of adenylyl cyclase, and elevation of intracellular cyclic AMP — leading to PKA and EPAC pathway activation (Drucker, 2018; Campbell & Drucker, 2013).

A C20 fatty-diacid chain is conjugated to the peptide backbone. This does not participate in receptor engagement itself; it promotes reversible albumin binding to extend circulating half-life and support the once-weekly regimens reported in the clinical literature (Urva et al., 2022).

The GLP-1 receptor is expressed on pancreatic β-cells, on neurons in the hypothalamus and brainstem, and in gastric, cardiovascular and immune tissues. Activation raises β-cell cAMP, potentiating glucose-dependent insulin secretion, and engages central satiety circuitry that reduces food intake and delays gastric emptying (Müller et al., 2019).

Retatrutide's GLP-1R activity is well characterised in reporter-gene and cAMP-accumulation assays and is broadly comparable in functional terms to the reference peptide GLP-1(7–37) (Coskun et al., 2022). This receptor arm is the shared pharmacology across every marketed incretin agonist — including semaglutide and tirzepatide — and is the primary reference axis against which the triple agonist is described.

GIP is the second major incretin hormone. Its receptor is expressed on pancreatic β-cells, adipocytes, bone and specific CNS regions. β-cell GIPR activation potentiates glucose-dependent insulin release in a manner complementary to GLP-1R engagement, while adipose GIPR activity is implicated in lipid handling (Campbell & Drucker, 2013).

Retatrutide activates GIPR with reported potency in the same order of magnitude as GLP-1R, giving it a dual-incretin profile comparable in principle to tirzepatide before glucagon activity is considered (Coskun et al., 2022). The role of GIPR agonism in weight regulation remains an area of active mechanistic investigation.

Endogenous glucagon acts primarily at hepatic GCGR to raise glucose output. Beyond the liver, glucagon-receptor signalling is associated with increased resting energy expenditure, hepatic lipid oxidation and thermogenic gene programmes in animal models (Finan et al., 2015).

Retatrutide adds meaningful GCGR agonism to its incretin-receptor profile. The design hypothesis — supported by the preclinical and clinical characterisation in Coskun et al. (2022) and Jastreboff et al. (2023) — is that pairing the glucose-lowering, appetite-reducing pharmacology of GLP-1/GIP with the energy-expenditure axis of glucagon produces a receptor signature distinct from any single- or dual-agonist reference.

Because glucagon-receptor activity is intrinsically hyperglycaemic in isolation, balance across the three receptors is central to the peptide's design rationale: incretin activity is required to offset direct GCGR-driven glucose output.

Single- and dual-agonist peptides access a defined range of metabolic pharmacology. Introducing glucagon-receptor engagement extends that range along an orthogonal axis — energy expenditure and hepatic lipid handling — while retaining the glucose- and appetite-regulating effects of the incretin arms. The result is a receptor signature that cannot be reproduced with GLP-1R alone or with GLP-1R/GIPR co-agonism, and that requires three-receptor assay coverage to characterise correctly.

For laboratory research, the practical implication is that assay design must span the three receptors: cAMP accumulation and β-arrestin recruitment in GLP-1R-, GIPR- and GCGR-expressing lines, ideally as a matched panel. Restricting characterisation to a single receptor systematically under-reports the peptide's pharmacology.

Dual incretin agonists (GLP-1R + GIPR) established the design principle that engaging more than one incretin receptor with a single peptide can produce a pharmacology greater than the sum of the parts. Retatrutide extends the principle by adding a third, mechanistically distinct axis — glucagon signalling — that is not incretin biology at all.

The mechanistic differences that follow are not gradations of the same activity: they are a new axis. In experimental terms, moving from a dual to a triple agonist changes the assay panel required (adding GCGR-expressing cell lines and hepatic-lipid readouts), the interpretive framework for observed effects (any change must be attributed across three receptors) and the reference peptides used as controls (glucagon and the earlier triagonist designs of Finan et al., 2015).